MacroGenics has a strong cash position ... three molecules with our three core platforms, our FC engineered, our DART bispecific and our ADC platform are being pursued for treatments for various ...

MacroGenics has a strong cash position of $240 million ... three molecules with our three core platforms, our FC engineered, our DART bispecific and our ADC platform are being pursued for treatments ...

MacroGenics has secured $475 million in non-dilutive ... in the development of prostate cancer using our three proprietary technologies, FC engineering, our bispecific DART technology, as well as our ...